| Antiretroviral Therapy | Category | Clarifications/Special considerations |
|---|---|---|
| a) Nucleoside reverse transcriptase inhibitors (NRTIs) | No assigned category | Giving antiretroviral medications (ARVs) to either the HIV-positive mother or the HIV-exposed infant or both can significantly reduce the risk of transmitting HIV through breastfeeding. Read More |
| Abacavir (ABC) | ||
| Tenofovir (TDF) | ||
| Zidovudine (AZT) | ||
| Lamivudine (3TC) | ||
| Didanosine (DDI) | ||
| Emtricitabine (FTC) | ||
| Stavudine (D4T) | ||
| b) Non-nucleoside reverse transcriptase inhibitors (NNRTIs) | ||
| Efavirenz (EFV) | ||
| Etravirine (ETR) | ||
| Nevirapine (NVP) | ||
| Rilpivirine (RPV) | ||
| c) Protease inhibitors (PIs) |
||
| Ritonavir-boosted atazanavir (ATV/r) | ||
| Ritonavir-boosted lopinavir (LPV/r) | ||
| Ritonavir-boosted darunavir (DRV/r) | ||
| Ritonavir (RTV) | ||
| d) Integrase inhibitors | ||
| Raltegravir (RAL) |